{"filing":{"accession_number":"0001171843-26-003931","cik":"0001540159","ticker":"EDSA","company_name":"Edesa Biotech, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"f8k_060226.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326003931/f8k_060226.htm"},"events":[{"id":3688,"run_id":3237,"accession_number":"0001171843-26-003931","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Edesa Biotech disclosed favorable exploratory clinical data for paridiprubart showing a 32% relative reduction in 28-day mortality in AKI patients and a 23% relative reduction in MAKE30 incidence, presented at the ERA Congress. While this represents material clinical progress for a biotech company's lead candidate, the disclosure emphasizes these are exploratory, post-hoc analyses not prespecified in the statistical plan, with nominal p-values not adjusted for multiplicity and explicit caution that confirmatory studies would be required. This clinical milestone does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, restatement, or litigation), making it best classified as other_material given its potential significance to investors assessing the company's pipeline prospects.","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-06-05","items":[{"id":4692,"accession_number":"0001171843-26-003931","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Edesa Biotech disclosed favorable exploratory clinical data for paridiprubart showing a 32% relative reduction in 28-day mortality in AKI patients and a 23% relative reduction in MAKE30 incidence, presented at the ERA Congress. While this represents material clinical progress for a biotech company's lead candidate, the disclosure emphasizes these are exploratory, post-hoc analyses not prespecified in the statistical plan, with nominal p-values not adjusted for multiplicity and explicit caution that confirmatory studies would be required. This clinical milestone does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, restatement, or litigation), making it best classified as other_material given its potential significance to investors assessing the company's pipeline prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:51:51.170707+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4692,"accession_number":"0001171843-26-003931","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Edesa Biotech disclosed favorable exploratory clinical data for paridiprubart showing a 32% relative reduction in 28-day mortality in AKI patients and a 23% relative reduction in MAKE30 incidence, presented at the ERA Congress. While this represents material clinical progress for a biotech company's lead candidate, the disclosure emphasizes these are exploratory, post-hoc analyses not prespecified in the statistical plan, with nominal p-values not adjusted for multiplicity and explicit caution that confirmatory studies would be required. This clinical milestone does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, restatement, or litigation), making it best classified as other_material given its potential significance to investors assessing the company's pipeline prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:51:51.170707+00:00","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-06-05"}]}